Navigation Links
NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Date:4/8/2013

BETHESDA, Md., April 8, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, filed its annual report on Form 10K today, reporting its financial results for the year ended December 31, 2012.  The report also shows strong progress in all areas of the Company's operations, enhancing the Company's leadership position in immune therapies for cancer.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

Year End 2012 Financial Results  During the twelve months ended December 31, 2012, the company used $22.8 million in cash for operating activities, compared to $14.7 million in cash for operating activities during the twelve months ended December 31, 2011.  The Company incurred an overall net loss (cash and non-cash) of $67.3 million or $5.72 per share, as compared to a net loss of $32.8 million, or $5.58 per share, for the twelve months ended December 31, 2011.

The increase in net loss was primarily due to non-cash accounting charges (i.e., inducement expense for debt reduction, amortization of prior stock issuances, beneficial conversion charges and other accounting adjustments) as well as the increased number of clinical trial sites open and recruiting across the US in the Company's Phase III clinical trial of DCVax®-L for GBM brain cancer, and expansion of the trial preparations in Europe, as noted below. 

Review of 2012 Progress Demonstrates Leadership In Immune Therapy SpaceAs described more fully below, the Company's progress during 2012 included the following:

  • major regulatory milestones in 3 countries (US, UK and Germany);
  • substantial expansion of the Company's Phase III clinical trial activities with
    '/>"/>

  • SOURCE Northwest Biotherapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
    2. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
    3. Susan Cain Will Kick Off 2013 ASAE Annual Meeting & Exposition, Dan Heath is Closing General Session Speaker
    4. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
    5. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
    6. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
    7. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
    8. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
    9. Archimedes Inc. Renews Annual Marketing Agreement with HealthEconomics.Com
    10. Palatin Technologies To Present At The 25th Annual ROTH Conference
    11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
    (Date:10/22/2014)... WriteResult, LLC – a premier provider ... with a team of researchers from Yale University’s School ... Collaborative to provide electronic questionnaire data collection through use ... started in May, aims to evaluate the impact of ... to and participation in urban agriculture to impact their ...
    (Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
    (Date:10/20/2014)... 2014 The report “Pharmacy Automation ... Packaging and Labeling Systems, Table-top Counters) by End-user ... Forecasts & Trends to 2019” analyzes and studies ... North America, Europe, Asia-Pacific, and the Rest of ... and 30 figures spread through 300 pages and ...
    Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
    ... , , , , , ... , , , , The ability ... means that trace amounts of DNA contaminants could serve as templates, resulting , ... mentioned below to avoid PCR contamination from sources such as: , ...
    ... , , , , , , ... are three types of primers that may be used for reverse transcription: , ... poly(A) + tail , at the 3' end of mammalian mRNA. ... , Random hexanucleotides, which bind ...
    ... , , , ... a billionfold. Thus, even minuscule amounts of a contaminant can ... positive result. Such contaminants are often products , ... researchers have developed methods to avoid such contamination. , ...
    Cached Biology Technology:Setting up the laboratory to avoid contamination 2Preventing Carry-over Contamination with Uracil-DNA Glycosylase 2
    (Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst firm ... half of the world,s population will have a chip-based ... Europe . Asia , ... market accounting for more than 60% of all National ... Acuity,s report  -- "The Global National eID ...
    (Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
    (Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
    Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
    ... Torriani is a plant pathologist. His most recent research ... where he analyzed a special class of genes that ... heavily on these enzymes when attacking a plant. But ... one gene came in different sizes in different individuals. ...
    ... A team of scientists from Worcester Polytechnic Institute ... Life Sciences and Bioengineering Center, have regenerated functional muscle ... clinical therapy to treat people who suffer major muscle ... coax mature human muscle cells into a stem cell-like ...
    ... Adelaide scientist says much more could be done to predict ... tuberculosis (TB) or foot-and-mouth disease - in Australian wildlife and ... have evaluated freely available software tools that provide a realistic ... used a combination of models to look at the possible ...
    Cached Biology News:Shedding light on the 'dark matter' of the genome 2Shedding light on the 'dark matter' of the genome 3Shedding light on the 'dark matter' of the genome 4Body rebuilding: Researchers regenerate muscle in mice 2Body rebuilding: Researchers regenerate muscle in mice 3New thinking required on wildlife disease 2
    Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
    ... Gel Loading Buffer contains a precipitant to ... and a tracking dye to allow the user ... Components ReddyRun™: ABgene ® s ... with the same buffer composition used in ReddyRun™ ...
    ... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,381-3) or ...
    Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
    Biology Products: